Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | PLA2G2A | P14555 | 18/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19859555 | 1.00 | EPHX2 (0.38) | EPHX2PLA2G2AALDH1A1HTT | |
| SCHEMBL19859496 | 0.82 | EPHX2 (0.36) | EPHX2PLA2G2A | |
| SCHEMBL19859497 | 0.82 | EPHX2 (0.36) | EPHX2PLA2G2A | |
| SCHEMBL21046976 | 0.79 | PLA2G2A (0.36) | EPHX2PLA2G2A | |
| SCHEMBL19859510 | 0.79 | PLA2G2A (0.36) | EPHX2PLA2G2A | |
| SCHEMBL19859508 | 0.79 | PLA2G2A (0.36) | EPHX2PLA2G2A | |
| SCHEMBL19859617 | 0.73 | CYP2D6 (0.38) | EPHX2PLA2G2A | |
| SCHEMBL18792739 | 0.70 | PTGER3 (0.38) | EPHX2PLA2G2AALDH1A1 | |
| SCHEMBL22679904 | 0.70 | GRIA2 (0.49) | ALDH1A1 | |
| SCHEMBL12304250 | 0.70 | TSHR (0.48) | EPHX2PLA2G2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3497098-A1 | FUMAGILLOL COMPOUNDS AND METHODS OF MAKING AND USING SAME | Zafgen, Inc. (US) | 2019-06-19 | — | — | EP | claimed |
| WO-2018031877-A1 | FUMAGILLOL COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. (US) | 2018-02-15 | — | — | WO | claimed |
| EP-3497098-A1 | FUMAGILLOL COMPOUNDS AND METHODS OF MAKING AND USING SAME | Zafgen, Inc. (US) | 2019-06-19 | — | — | EP | disclosed |
| US-20190169181-A1 | FUMAGILLOL COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2019-06-06 | — | — | US | disclosed |
| WO-2018031877-A1 | FUMAGILLOL COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. (US) | 2018-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169181-A1 | FUMAGILLOL COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, DNPEP, FOLH1 | EPHX2 246/4885PLA2G2A 1043/4885ALDH1A1 608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.